We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+10.49%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.11B
AUM Growth
+$53M
Cap. Flow
-$7.26M
Cap. Flow %
-0.65%
Top 10 Hldgs %
81.32%
Holding
36
New
7
Increased
8
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$26.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$11M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$10.3M
4
BLUE
bluebird bio
BLUE
+$10.2M
5
VERV
Verve Therapeutics
VERV
+$7.14M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$41.5M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.2M
3
INSM icon
Insmed
INSM
+$9.8M
4
FOLD
Amicus Therapeutics
FOLD
+$1.71M
5
NVCR icon
NovoCure
NVCR
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$503M
$3.03M 0.27%
732,400
– –
MIRM icon
27
Mirum Pharmaceuticals
MIRM
$6.04B
$1.91M 0.17%
64,700
– –
VNDA icon
28
Vanda Pharmaceuticals
VNDA
$314M
$1.18M 0.11%
278,985
– –
YARW
29
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$1.04M 0.09%
+8,909
New +$1.39M
TVTX icon
30
Travere Therapeutics
TVTX
$5.86B
$995K 0.09%
110,719
-55,350
-33% -$403K
TSHA icon
31
Taysha Gene Therapies
TSHA
$2.05B
$938K 0.08%
+529,861
New +$1.06M
SGHT icon
32
Sight Sciences
SGHT
$456M
$897K 0.08%
+173,790
New +$536K
ALDX icon
33
Aldeyra Therapeutics
ALDX
$91.7M
$791K 0.07%
225,465
+64,665
+40% +$200K
URGN icon
34
UroGen Pharma
URGN
$2.39B
$368K 0.03%
24,500
– –
KZR
35
DELISTED
Kezar Life Sciences
KZR
– –
-65,620
Closed -$781K
TCMD icon
36
Tactile Systems Technology
TCMD
$555M
– –
-27,100
Closed -$381K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q4 2023 Portfolio in Review

As of Q4 2023, Palo Alto Investors held 36 positions worth $1.11B, up 5% from $1.06B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Palo Alto Investors's Q4 2023 filing shows 7 new, 8 increased, 10 reduced and 2 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 154,437 shares worth $29.6M. The largest sale was United Therapeutics, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q4 2023 buy was Alnylam Pharmaceuticals: 154,437 shares worth $29.6M.
  • Palo Alto Investors added most to Sarepta Therapeutics in Q4 2023, an estimated $10.3M increase.
  • Palo Alto Investors's biggest Q4 2023 reduction was United Therapeutics, cutting an estimated $41.5M.
  • Palo Alto Investors fully exited Kezar Life Sciences in Q4 2023, selling an estimated $781K.
  • Palo Alto Investors's ten largest holdings make up 81% of its $1.11B portfolio in Q4 2023.
  • Palo Alto Investors opened 7 new positions and closed 2 in Q4 2023.
  • Palo Alto Investors's portfolio value rose 5% quarter-over-quarter to $1.11B.

Based on Palo Alto Investors's 13F filing for Q4 2023, filed 14 Feb 2024.